As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to OSTP in January 2023 about the Office of Science and Technology Policy Request for Information: Clinical Research Infrastructure and Emergency Clinical Trials can be found below.